Marksans Pharma Performance
- Today's Low
- ₹214
- Today's High
- ₹221
- 52 Week Low
- ₹155
- 52 Week High
- ₹271
- Open Price₹214
- Previous Close₹212
- Volume1,813,420
- 50 DMA₹191.02
- 100 DMA₹186.05
- 200 DMA₹190.47
Marksans Pharma Chart
Investment Returns
- Over 1 Month + 15.8%
- Over 3 Month + 26.54%
- Over 6 Month + 16.66%
- Over 1 Year -10.71%
Smart Investing Starts Here Start SIP with Marksans Pharma for Steady Growth!
Marksans Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 27.7
- PEG Ratio
- -12.7
- Market Cap Cr
- 9,981
- P/B Ratio
- 3.6
- Average True Range
- 9.04
- EPS
- 7.95
- Dividend Yield
- 0.4
- MACD Signal
- 8.68
- RSI
- 69.24
- MFI
- 77.47
Latest Stock News Updates
This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc
- Business Line
- 1 month 3 weeks ago
Pharmaceuticals company Marksans Pharma announced Q3FY26 results Operating revenue stood at Rs 754.4 crore, up by 10.6% YoY, attributed to strong traction in the US and UK markets, supported by robust momentum from new product launches and market share gains. Gross profit stood at Rs 438.2 crore, up by 14.3% YoY, with gross margin of 58.1%. EBITDA stood at Rs 160.7 crore; EBITDA margin at 21.3%, expanded 217 bps YoY. EPS was Rs 2.5. Mark Saldanha, Managing Director, said: “We delivered a stable and resilient performance in Q3FY26, with operating revenue growing 10.6% YoY, supported by steady execution across key markets and improved seasonal demand. Margins expanded sequentially, driven by soft raw material costs, favorable currency movements, and an improving product mix, while EBITDA growth reflected operating leverage. During the quarter, we took measured steps to strengthen our global footprint through new subsidiaries in Europe and Canada, positioning the Company for long-term growth in regulated markets. We remain disciplined, executionfocused, and committed to delivering sustainable growth and long-term shareholder value.” Result PDF
- Trendlyne
- 3 months 2 weeks ago
Conference Call with Marksans Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
- Trendlyne
- 6 months 1 week ago
Marksans Pharma Financials
Marksans Pharma Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹203.54
- 50 Day
- ₹191.02
- 100 Day
- ₹186.05
- 200 Day
- ₹190.47
Resistance and Support
- R3 230.46
- R2 225.91
- R1 223.08
- S1 215.70
- S2 211.15
- S3 208.32
Marksans Pharma Corporate Actions - Bonus, Splits, Dividends
About Marksans Pharma
- NSE Symbol
- MARKSANS
- BSE Symbol
- 524404
- Chairman & Managing Director
- Mr. Mark Saldanha
- ISIN
- INE750C01026
Similar Stocks to Marksans Pharma
Popular Stocks
Marksans Pharma FAQs
Marksans Pharma share price is ₹220 As on 25 May, 2026 | 23:14
The Market Cap of Marksans Pharma is ₹9981.4 Cr As on 25 May, 2026 | 23:14
The P/E ratio of Marksans Pharma is 27.7 As on 25 May, 2026 | 23:14
The PB ratio of Marksans Pharma is 3.6 As on 25 May, 2026 | 23:14
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.